Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 13, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 19, 2026
Reply to: Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 17, 2025
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC.
Journal: Lancet (London, England)
Published: October 05, 2025
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Journal: Molecular cancer therapeutics
Published: September 05, 2025
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.
Journal: Cancer discovery
Published: July 09, 2025
Last Updated: 09/26/2026